Cambridge Investment Research Advisors
RETA

Cambridge Investment Research Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,192
Closed -$223K – 3293
2023
Q2 		$223K Buy
+2,192
New +$207K ﹤0.01% 2790
2021
Q4 		– Sell
-2,388
Closed -$240K – 3301
2021
Q3 		$240K Buy
2,388
+94
+4% +$11K ﹤0.01% 2647
2021
Q2 		$325K Buy
2,294
+67
+3% +$7.57K ﹤0.01% 2408
2021
Q1 		$222K Buy
2,227
+82
+4% +$9.56K ﹤0.01% 2533
2020
Q4 		$265K Sell
2,145
-200
-9% -$26.3K ﹤0.01% 2250
2020
Q3 		$228K Sell
2,345
-150
-6% -$18.7K ﹤0.01% 2151
2020
Q2 		$389K Hold
2,495
– – ﹤0.01% 1695
2020
Q1 		$360K Buy
2,495
+50
+2% +$9.65K ﹤0.01% 1565
2019
Q4 		$500K Buy
+2,445
New +$446K ﹤0.01% 1578

Other funds holding RETA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cambridge Investment Research Advisors's RETA Position: Q3 2023 in Review

Cambridge Investment Research Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2,192 shares — an estimated $223K sold.

Cambridge Investment Research Advisors first reported a position in RETA in Q4 2019 and held it in 9 quarters. The position peaked at $500K in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • Cambridge Investment Research Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 2,192 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $223K.
  • Cambridge Investment Research Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 9 quarters.
  • Cambridge Investment Research Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $500K in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.